Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.

The combination of 102-5 anti-CLPTM1L and carboplatin resulted in robust killing with a highly significant interaction between anti-CLPTM1L treatment and carboplatin treatment (ANOVA p < 0.02). 102-5 anti-CLPTM1L treatment resulted in decreased Akt phosphorylation at threonine 308 in both HeyA8-Cis R and A2780-Cis R cells, including those treated in combination with cisplatin (Fig. 2e ).

also in 132,142 other papers